US company Moderna begins work on vaccine against new SARS-CoV-2 variant ‘Omicron’
US-based biotechnological company Moderna works on a new booster vaccine against a new SARS-CoV-2 variant, B.1.1.529, which was assigned the name ‘Omicron,’ the company said in a statement.
"The recently described Omicron variant includes mutations seen in the Delta variant that are believed to increase transmissibility and mutations seen in the Beta and Delta variants that are believed to promote immune escape," the statement reads.
"A booster dose of an authorized vaccine represents the only currently available strategy for boosting waning immunity," according to the company. "The Moderna COVID-19 vaccine (mRNA-1273) is authorized as a booster for many populations at the 50 µg dose level."
"The Company is working rapidly to test the ability of the current vaccine dose to neutralize the Omicron variant and data is expected in the coming weeks," the statement added.
- USD 1,7000 0,00%
- EUR 1,9256 +0,02%
- GBP 2,3041 -0,30%
- RUB 0,0220 -0,45%